ArticleScientific reports2026
ZUP1 contributes to cisplatin resistance and treg-related signaling in non-small cell lung cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acquired cisplatin resistance limits platinum chemotherapy efficacy in non-small cell lung cancer (NSCLC) and is accompanied by tumor immune microenvironment (TME) remodeling. We integrated public NSCLC single-cell RNA-seq datasets to compare cellular composition and CellChat-inferred communication between post-chemotherapy remission and relapse/resistant tumors, and validated ZUP1 expression and prognostic relevance in TCGA and external cohorts. In cisplatin-resistant A549/R and SK-MES-1/R cells, we generated stable ZUP1 knockdown and assessed proliferation, tumorsphere growth and formation, apoptosis (Annexin V/PI) and BAX/BCL2 expression, and xenograft growth. Tumor cell-peripheral Treg co-cultures were used to quantify the proportion of FOXP3⁺ cells within the gated CD4⁺ population. Natural-product screening was guided by molecular docking, and ZUP1-compound binding was evaluated by surface plasmon resonance (SPR). Peimisine responses were compared between parental and cisplatin-resistant cells. In A549/R cells, experimentally measured viability across a peimisine-cisplatin concentration matrix and cisplatin dose-response curves at fixed peimisine concentrations were used to evaluate changes in cisplatin sensitivity. Resistant tumors exhibited remodeled cellular composition and enhanced intercellular communication, including increased epithelial-to-Treg signaling. ZUP1 was upregulated in resistant models and associated with unfavorable prognosis. ZUP1 knockdown suppressed growth and tumorsphere formation, increased apoptosis, reduced tumorigenicity in vivo, and reduced the proportion of CD4⁺FOXP3⁺ Treg-like cells in co-culture. Peimisine directly bound ZUP1 by SPR, inhibited resistant cell growth, and was associated with lower estimated cisplatin IC₅₀ values in A549/R cells at fixed peimisine concentrations. ZUP1 contributes to the maintenance of cisplatin-resistant growth and is associated with enhanced Treg-related immunosuppressive signaling in NSCLC. Peimisine directly binds ZUP1 and may serve as a preliminary natural-product lead for further target-validation and combination studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.